Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions for regenerating tissue that has deteriorated, and methods for using such compositions

a tissue and composition technology, applied in general culture methods, dentistry preparations, dental prosthetics, etc., can solve the problems of limited debridement, limited access to root surfaces and bony defects, and no treatment is wholly satisfactory, so as to promote tissue regeneration, avoid elicitation of immune response and inflammation, and improve tissue regeneration

Inactive Publication Date: 2005-08-25
ISOLAGEN INT
View PDF16 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The present invention provides a method for promoting regeneration of tissue in a subject that has degenerated as a result of a disease or disorder. The method involves injecting a pharmaceutical composition of autologous fibroblasts into the tissue to be regenerated. The fibroblasts are taken from the subject's own body and are expanded in a culture medium before being injected back into the subject. The method can be used to treat various tissue degeneration and defects, including those of the oral mucosa, periodontal tissue, skin, and bone. The invention also includes a device for delivering the pharmaceutical composition to the site of tissue degeneration or defect."

Problems solved by technology

Particularly with respect to severe periodontitis, none of the currently available treatments are wholly satisfactory.
However, without resorting to surgical procedures, access to root surfaces and bony defects is restricted, and only limited debridement is possible.
As a result, nonsurgical scaling and root planing is insufficient to treat more severe cases of periodontitis, and it is necessary to resort to more aggressive surgical techniques.
Currently available surgical approaches entail substantial patient discomfort and fail to consistently provide satisfactory outcome.
Yet none of these approaches have achieved more than marginal success [Jeffcoat, M. K., et al., J. Am. Dent. Assoc., 128:713-724 (1997)].
In particular, there are a number of deleterious side effects associated with the use of antibiotics, along with risks such as drug sensitivity and the emergence of antibiotic-resistant pathogens.
Tetracyclines in particular have shown promise as inhibitors of extracellular collagenases, but cause the same side effects associated with antibiotics in general.
Modified forms of tetracycline have been developed which are non-antimicrobial and retain their ability to inhibit collagenases, but these chemically modified tetracyclines are not commercially available.
In summary, none of the nonmechanical approaches to treating periodontitis have been able to offer more than modest, short term enhancement of traditional mechanical debridement.
A great deal of research has been directed to methods of regenerating periodontal tissue lost as a consequence of periodontal disease, but as yet no wholly satisfactory method is available.
Clinicians using natural bone grafts have had limited success in inducing new bone growth.
Problems associated with the use of autografts include the need for a second surgical site and, in some cases, fresh grafts may be associated with root resorption.
Histologic findings, however, indicate that, in general, synthetic grafts act primarily as space fillers, with little if any regeneration.
A significant disadvantage of using a nonresorbable membrane is the requirement of a second surgical procedure after approximately six weeks to remove the membrane.
In summary, none of the currently available treatments for periodontal disease is wholly satisfactory, particularly with regards to regenerating periodontal tissue lost as a result of periodontitis.
There is currently no wholly satisfactory means of correcting these defects.
However, the use of these compositions comprises inherent limitations.
For example, the use of mineral oil, paraffin and similar oils and waxes has resulted in complications such as local chronic edema, lymphadenopathy, scarring and ulcerations (Devore et al., Effectiveness of injectable filler materials for smoothing wrinkle lines and depressed scars.
The use of reconstituted bovine collagen to correct defects or augment tissue also possesses inherent limitations.
For example, it has been reported that reconstituted bovine collage is only moderately effective, and is associated with infrequent, but controversial, adverse reactions.
However, this material also possess inherent limitations.
Specifically gelatin matrix does not appear to have applications in the treatment of wrinkle lines.
Moreover, since a large bore needle (27 gauge or greater) is used to inject the gelatin matrix into the subject's skin, treatment with gelatin results in greater discomfort and pain to the subject as opposed to the injection of other fillers.
Also, a very large bore needle (as large as 16 gauge) is needed to inject the fat into a subject, resulting in great pain, moderate bruising, and formation of visible puncture holes.
Moreover, fat injections are subject to rapid resorption, and must be repeated in order to maintain skin augmentation or defect correction.
The use of autologous, injectable dermal collagen to correct defects or augment tissue has also met with limited success.
For example, if large concentrations of collagen are injected, a 27 gauge needle or larger is used, resulting in the infliction of pain on the subject.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example i

Administration of a Suspension of Autologous Fibroblasts to Promote Tissue Regeneration and Correct Defects in Tissues

Method of Obtaining an Injectable Cell Pharmaceutical Composition

[0074] As disclosed above, one embodiment of the present invention comprises a method for regenerating tissue that has been damaged in a subject as a result of a disease or disorder in the subject, wherein the method comprises providing a pharmaceutical composition comprising of autologous, passaged fibroblasts substantially free of immunogenic proteins (e.g., culture medium serum-derived proteins), identifying a site of tissue degeneration or a defect in tissue, injecting an effective amount of the pharmaceutical composition into the tissue at the site of the tissue degeneration or defect so that the tissue is augmented, and the growth of tissue is promoted at the site of degenerated tissue.

[0075] A disease or disorder which promotes tissue degeneration in a subject, and can be treated with this asp...

example ii

A Composition for Promoting the Regeneration of Tissue that Has Degenerated in a Subject

[0092] Also disclosed in the present invention is a composition for promoting the regeneration of tissue that degenerated in a subject. Such degeneration can occur as a result of periodontal disease, trauma, dermatoses, recurrent aphthous stomatitis, or infections to name only a few. Other relevant diseases and disorders are listed above. Moreover, examples of periodontal disease which can cause tissue degeneration include periodontal degeneration, gingivitis, or non-healing wounds of the palatal mucosa or gingival mucosa. Moreover, a composition of the present invention can also be used to correct defects in tissue of a subject, such as, for example, defects in the palatal mucosa, gingival mucosa, or defects in skin, e.g., any of those described above. Such compositions can be used, for example, for healing extraction sockets after extraction of a tooth. Moreover, they can be used to fill extra...

example iii

An Injectable Composition for Correcting Skin Defects and Augmenting Tissue in a Subject

[0112] As explained above, the present invention extends to an injectable composition for correcting a defect in skin of a subject, or augmenting tissue of a subject, wherein the injectable composition comprises passaged autologous fibroblasts substantially free of immunogenic proteins (e.g., culture medium serum-derived proteins), and a biodegradable, acellular injectable filler material. Examples of skin defects that can be treated with the present invention include scars, particularly facial scars resulting from trauma or acne, or wrinkles. Any of the other skin and other tissue defects listed above can also be treated with the present invention. Furthermore, the present invention can be used to augment tissue in a subject. For example, the injectable composition of the present invention can be injected into the lips of a subject in order to make the lips larger and fuller, or it can be injec...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
thicknessaaaaaaaaaa
concentrationaaaaaaaaaa
Login to View More

Abstract

A composition for promoting regeneration of tissue which has degenerated in a subject as a result of a disease or disorder and a method of using the composition is provided. The composition comprises a biodegradable acellular matrix, and passaged autologous fibroblasts substantially free of immunogenic proteins, e.g., culture medium serum-derived proteins, integrated within the matrix. The method of using the composition to promote regeneration of tissue involves placing the composition on a site of degenerated tissue in a subject so that the composition promotes tissue regeneration at the site. The composition and the method of its use have applications promoting regeneration of tissue (i) that has degenerated as a result of numerous diseases or disorders or (ii) that has a defect, including, but not limited to, defects of the oral mucosa, trauma to the oral mucosa (e.g., extraction of a tooth), periodontal disease, diabetes, cutaneous ulcers, venous stasis, scars of the skin, or wrinkles of the skin. Also provided is an injectable composition comprising any type of collagen and passaged autologous fibroblasts substantially free of immunogenic proteins, e.g., culture medium serum-derived proteins, for correcting defects in skin, such as wrinkles or scars, and for augmenting tissue in the subject, particularly facial tissue.

Description

[0001] This application is a continuation-in part and claims priority of U.S. application Ser. No. 09 / 316,245, filed May 21, 1999, which is a continuation-in-part and claims priority of U.S. application Ser. No. 09 / 083,618, filed May 22, 1998. U.S. application Ser. Nos. 09 / 316,245 and 09 / 083,618 are incorporated herein by reference in their entirety.FIELD OF THE INVENTION [0002] The present invention concerns the regeneration of tissues in a subject that have degenerated as a result of a disease or disorder in the subject. More particularly, the present invention concerns novel compositions for use in surgical and nonsurgical techniques that promote regeneration of tissue whose mass has been diminished due to a disease or disorder in a subject, correct defects in the skin of subjects, or augment tissue in subjects. Also disclosed is the use of a novel composition in conjunction with a biodegradable acellular matrix for ameliorating defects in the tissues, and methods for using the n...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61F2/00A61F13/00A61K6/00A61K35/12A61K35/34A61L27/12A61L27/22A61L27/24A61L27/36A61L27/38A61L27/58A61L31/00A61L31/02A61L31/04A61L31/14C12N5/00C12N5/02C12N5/077
CPCA61F2013/00374A61L2400/06A61F2310/00365A61F2310/00383A61K35/12A61K35/34A61L27/12A61L27/22A61L27/222A61L27/24A61L27/3608A61L27/3629A61L27/3641A61L27/365A61L27/3683A61L27/3687A61L27/3804A61L27/3839A61L27/3847A61L27/3895A61L27/58A61L31/005A61L31/026A61L31/043A61L31/044A61L31/045A61L31/148C12N5/0068C12N5/0656C12N2533/18C12N2533/54C12N2533/90A61F2310/00293A61P43/00
Inventor BOSS, WILLIAM K. JR.MARKO, OLGA
Owner ISOLAGEN INT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products